Nano Dimension Ltd.

Nano Dimension Ltd. announced the termination of its corporate headquarters lease, effective December 31, 2026, as part of ongoing cost savings initiatives. The original long-term lease, set to expire in 2031, was negotiated for termination, substantially reducing future lease obligations. The company expects to eliminate approximately $38 million in cumulative future lease costs, resulting in an estimated $25 million in cumulative net cash savings after a $13 million termination payment.

Nano Dimension Ltd. issued a press release to provide additional details on its proposed business combination with Infinite Epigenetics, Inc., an AI-powered preventive health and diagnostics company. The company highlighted Infinite's established science, proprietary data, and commercial success in the over $90 billion chronic disease diagnostics market. Nano Dimension also addressed Murchinson Ltd.'s concerns, emphasizing the value creation opportunity, the 20% premium for Nano's cash value, and the retention of contingent value rights for shareholders.

Nano Dimension Ltd. issued a shareholder update to provide additional details and defend its proposed business combination with Infinite Epigenetics, addressing concerns raised by Murchinson. The company highlights Infinite Epigenetics as a real business with proven science in the epigenetics market, an operating diagnostic platform with existing commercial revenue, and a proprietary biological AI platform. Nano Dimension states that the transaction offers shareholders a 20% premium on the company's cash value and represents a strategic shift into the significantly larger AI-powered preventive health and diagnostics market.

Nano Dimension Ltd. has entered into a non-binding term sheet to acquire Infinite Epigenetics, Inc. in a proposed business combination. The transaction, valued at $890 million for Infinite Epigenetics, will be structured as a stock-for-stock merger, with existing Nano Dimension shareholders expected to retain a meaningful minority ownership in the combined entity. The combined company will operate under the Infinite Epigenetics name and trade on Nasdaq under the ticker symbol IEAI. The deal includes binding exclusivity provisions and a potential expense reimbursement for Infinite Epigenetics if a definitive agreement is not reached by a specific date.

Nano Dimension Ltd. announced a non-binding term sheet for a proposed business combination with Infinite Epigenetics, an AI-powered preventive health and diagnostics company. The transaction values Infinite Epigenetics at $890 million and aims to deploy Nano Dimension's capital base and Nasdaq listing into a high-growth healthcare AI opportunity. Existing Nano shareholders are expected to retain a meaningful minority ownership, with their shares valued at a 20% premium to Nano's estimated net cash at closing, and the combined company is projected to have over $400 million in cash. Infinite Epigenetics focuses on a $90B+ U.S. clinical diagnostics market, leveraging a proprietary biological AI platform and over 120,000 epigenetic samples collected since 2020.

Nano Dimension Ltd. has announced an Extraordinary General Meeting of Shareholders to be held on July 31, 2026. The meeting will address several proposals, including the continuation of the company's strategic alternatives review process and proposals from certain shareholders to amend the company's articles of association and remove directors. The Board of Directors recommends voting FOR proposals related to the strategic review and amending Article 39, but AGAINST proposals to add new articles and remove/elect directors.

Nano Dimension Ltd. CEO David Stehlin updated shareholders on the company's strategic plan, which includes streamlining operations, monetizing product lines, and evaluating future growth opportunities. The company has made significant progress, reducing standalone operating expenses by 22% in Q1 2026 and declining operating cash burn since Q3 2025. Key divestments include the AME and Fabrica product lines for up to $12.5 million and the all-cash sale of Markforged for $42.5 million, expected to reduce annualized cash burn by $25 million. The company maintains a strong liquidity position with $441.6 million in cash and equivalents as of March 31, 2026, and expects to announce its path forward in the coming weeks.

Nano Dimension Ltd. announced a definitive agreement to sell its wholly-owned subsidiary, MarkForged, Inc., to Stratasys Ltd. for $42.5 million in an all-cash transaction. This move is a key part of Nano Dimension's three-phase strategic plan, specifically Phase 2, which focuses on monetizing product lines and strengthening the balance sheet. The company anticipates that this transaction will reduce its annualized cash burn by approximately $15 million. Nano Dimension will retain the Markforged Metal Binder Jetting product line, and the deal is expected to close in the second half of 2026.

Nano Dimension Ltd. issued a letter to shareholders, rejecting Murchinson Ltd.'s latest attempt to gain effective control of the company. Murchinson filed an amended Schedule 13D/A, seeking to replace three of Nano Dimension's five directors, including two it had previously nominated. The Board stated that Murchinson has not presented a credible strategic plan and is focused solely on controlling Nano Dimension's balance sheet. Concurrently, the Board is actively pursuing a comprehensive strategic alternatives review process to maximize shareholder value, which it expects to conclude soon.

Nano Dimension Ltd. reported a significant increase in net loss for Q1 2026, reaching $(69.66) million, primarily driven by a $40.39 million goodwill impairment related to its Markforged FFF product line. Despite this, total revenue grew to $29.73 million, up from $14.40 million in Q1 2025. The company also noted an ongoing independent process to evaluate strategic alternatives and acknowledged escalating geopolitical tensions as risk factors.